Latest Carolina Liquid Chemistries News
Aug 9, 2020
Published on Carolina Liquid Chemistries (CLC), Greensboro, NC, is now offering test kits for COVID-19 that have been granted FDA emergency use authorization (EUA). Among the test kits are two real-time RT-PCR (reverse transcriptase polymerase chain reaction) test kits intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasal swabs, nasopharyngeal swabs, oropharyngeal swabs, and sputum from individuals suspected of Covid-19. CLC also offers manual and automated test kits intended for the qualitative detection of antibodies to SARS-CoV-2. In addition to these FDA EUA-granted tests, CLC also offers supplies such as swabs and viral transport media (VTM). “As case numbers have increased, so has demand for testing and the importance of trustworthy supply sources,” says CLC founder and CEO Phillip Shugart. “Carolina Liquid Chemistries has been sourcing and manufacturing diagnostic test kits for over 25 years. It made sense for us to leverage our product sourcing capability to fill this need in the healthcare supply chain.” The DiaCarta RT-PCR QuantiVirus SARS-CoV-2 Test Kit from DiaCarta, Richmond, Calif, targets three viral genes (Orf1ab, N and E) and has sensitivity of 100 copies per mL of SARS-CoV-2 with a 95% confidence. The lateral flow COVID-19 IgG/IgM Rapid Test Device, manufactured by Assure Tech, Hangzhou, China, is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. Results are produced in 15 minutes. CLC also now carries sample collection and transportation supplies, including ultra-thin nasal and nasopharyngeal flocked swabs and Bartels FlexTrans Medium, an FDA 510(k) cleared viral transport medium (VTM) intended to stabilize viruses and suppress microbial contamination during transport of clinical specimens from the point of collection to the testing site. Prior to use, Bartels FlexTrans VTM can be conveniently stored at room temperature.